Cargando…
Early hypertension is associated with better clinical outcomes in gastric cancer patients treated with ramucirumab plus paclitaxel
Anti-vascular endothelial growth factor (VEGF) therapeutics such as bevacizumab, which are widely used in cancer treatment, commonly leads to hypertension. Moreover, bevacizumab-induced hypertension is associated with improved clinical outcomes in several cancers. We retrospectively analyzed 89 pati...
Autores principales: | Fukuda, Naoki, Takahari, Daisuke, Wakatsuki, Takeru, Osumi, Hiroki, Nakayama, Izuma, Matsushima, Tomohiro, Ichimura, Takashi, Ogura, Mariko, Ozaka, Masato, Suenaga, Mitsukuni, Shinozaki, Eiji, Chin, Keisho, Yamaguchi, Kensei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5880598/ https://www.ncbi.nlm.nih.gov/pubmed/29632638 http://dx.doi.org/10.18632/oncotarget.24635 |
Ejemplares similares
-
Retrospective study of RAS/PIK3CA/BRAF tumor mutations as predictors of response to first-line chemotherapy with bevacizumab in metastatic colorectal cancer patients
por: Nakayama, Izuma, et al.
Publicado: (2017) -
Treatment features of systemic chemotherapy in young adults with unresectable advanced or recurrent gastric cancer
por: Nakayama, Izuma, et al.
Publicado: (2018) -
Two Cases of Long-Term Survival of Advanced Colorectal Cancer with Synchronous Lung Metastases Treated with mFOLFOX6/XELOX + Bevacizumab
por: Ushida, Yuta, et al.
Publicado: (2018) -
Managing a gastrointestinal oncology practice in Japan during the COVID-19 pandemic: single institutional experience in The Cancer Institute Hospital of Japanese Foundation for Cancer Research
por: Takahari, Daisuke, et al.
Publicado: (2020) -
Phase II trial of biweekly cetuximab and irinotecan as third‐line therapy for pretreated KRAS exon 2 wild‐type colorectal cancer
por: Osumi, Hiroki, et al.
Publicado: (2018)